In recent years NfL has evolved as a powerful marker of disease severity in neurological disorders, especially in multiple sclerosis and neurodegenerative diseases such as Alzheimer’s disease, but also in acute neurological diseases such as ischemic stroke or traumatic brain injury1–4. This evidence concerns the gene NEFL and early-onset autosomal dominant Alzheimer disease.